Cognitive Functioning & Neuroprotection In Schizophrenia

Wednesday, June 26, 2019 | 12pm ET | 9am PT

Schizophrenia has a worldwide prevalence of approximately 1%. Individuals living with the disease often experience neurocognitive deficits, as well as poor memory and attention, which are considered core symptoms for the illness. Current evidence also suggests that neuroinflammation, a byproduct of neurotransmitter dysfunctions as a result of increased pro-inflammatory cytokines, may play a role in cognitive dysfunction and neurodegeneration in serious mental illnesses, such as schizophrenia. Recent evidence suggests that cognitive deficits may be present even before the onset of illness, making them targets for potential early intervention. Neuroprotective strategies that aim to address these factors exist. However, these treatments have limitations.

In this webinar, hear from Dr. René Kahn and Dr. Christoph Correll, as they discuss the trajectory of cognition in the course of illness for schizophrenia and describe potential strategies for measuring cognition. Speakers will also explore the evidence surrounding impacts to patient functioning and address the benefits and risks of a variety of potential neuroprotective strategies.

Speakers are paid consultants to Otsuka Pharmaceutical Development & Commercialization, Inc.

Visit www.PsychU.org to learn more and register today!